The Socioeconomic Evaluation of Medicines: A New Dimension

  • S. R. Walker
Conference paper
Part of the Health Systems Research book series (HEALTH)


In moving from traditional endpoints to innovative outcomes in determining the benefits of medicines, five aspects should be considered, namely, the key issues to be addressed, the need for such a change direction, the benefits of the socioeconomic approach, the opportunities available in estimating benefits, and the principles to be considered and implemented.


Health Care Expenditure Obstructive Lung Disease Life Assessment Socioeconomic Benefit Innovative Outcome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ware JE, Brook RH, Davies-Avery A, Lohv KN (1981) Choosing measures of health studies for individuals and general population. Am J Public Health 71:620–625PubMedCrossRefGoogle Scholar
  2. 2.
    Buxton MJ, Drummond MR (1990) Quality of life measurement in the development of medicines. Pharmaceut J 3 Mar:260–262Google Scholar
  3. 3.
    Read JL (1988) From medical to socioeconomic evaluation of drug therapy. In: van Eimeren W, Horisberger B (eds) Socioeconomic evaluation of drug therapy. Springer, Berlin Heidelberg New York Tokyo, pp 72–81Google Scholar
  4. 4.
    Spilker B (1990) Quality of life assessment in clinical trials. Raven, New YorkGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • S. R. Walker

There are no affiliations available

Personalised recommendations